Back to School: How biopharma can reboot drug development. Access exclusive analysis here

NICE amends Lucentis recommendation

The U.K.'s NICE amended a decision on the use of Lucentis ranibizumab from Novartis (NVS; SWX:NOVN) for wet age-related macular degeneration (AMD) to

Read the full 233 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE